Sydney M Crago

Theodore Leng, MD, MS, speaks about his ASRS presentation, focusing on the FARETINA-DME Study

Ahead of the ASRS meeting, Rishi P. Singh, MD, previews results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy

Carl J. Danzig, MD, discusses efficacy, safety, and durability of faricimab in macular oedema due to retinal vein occlusion

Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal geographic atrophy

Four retina specialists share what they're most looking forward to at the 2024 ASRS meeting

Jennifer I. Lim, MD, FARVO, FASRS, discusses her ASRS presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy"

Companies in the retina space announced presentations ahead of the American Society of Retina Specialists meeting, to be held 17-20 July

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

A preview of presentations from 4D Molecular Therapeutics and Adverum Biotechnologies

At the 2024 ARVO meeting, Andrew D. Pucker, OD, PhD, presented a paper on measuring meibomian gland morphology

At this year's ARVO meeting, the Eye Care Network got a glimpse at the future of paediatric myopia control research

Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation

Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

At this year's ARVO meeting, new data from the BLINK2 study show axial growth rates after discontinuing soft multifocal contact lens wear

Ahead of the meeting, several companies previewed product pipeline announcements and research data presentations

During the month of May, Prevent Blindness will offer fact sheets, videos and other resources for IRD education

The online tool shows vision loss simulations for diabetic macular oedema, diabetic retinopathy, age-related macular degeneration and other retinal diseases

I-SCREEN will bring together 12 institutions across Europe, including Queen’s University Belfast

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

The approval marks the first new steroid on the US ophthalmic market in more than 15 years

Sydney M Crago, editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial, presented at the 2024 Angiogenesis Symposium

The study illustrates efficacy of AVT06 as compared with aflibercept (Eylea) for neovascular age-related macular degeneration

Catch up on Modern Retina's top stories, and ones you may have missed in 2023

EXN407 has the potential to be the first topical treatment for diabetic retinopathy and diabetic macular oedema

The study results will help to identify dosing levels for future clinical trials

At this year’s EURETINA meeting, retina specialists highlighted important developments in diabetic macular oedema and diabetic retinopathy research

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

At AAO 2023, Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept for diabetic macular oedema